Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
Open Access
- 8 June 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (5), 3870
- https://doi.org/10.15829/1560-4071-2020-3870
Abstract
Patients with heart failure with reduced ejection fraction (HFrEF), despite optimal evidence-based treatment, have a high residual risk of adverse outcomes. The favorable results of studies on cardiovascular safety and the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D), including outcomes associated with heart failure, were the reason for studying the effectiveness in patients with HFrEF regardless of the T2D status. For the first time in the DAPA-HF study, the SGLT2 inhibitor dapagliflozin in patients with HFrEF showed a positive effect on hard endpoints. Data of the secondary analysis confirmed the effectiveness of dapagliflozin regardless of the T2D status, therapy, age, and quality of life. The results of DAPA-HF have become a serious statement for changing the standards of the guideline-recommended therapy of HFrEF.Keywords
This publication has 32 references indexed in Scilit:
- Clinical Update: Cardiovascular Disease in Diabetes MellitusCirculation, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCirculation, 2015
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart FailureJACC: Heart Failure, 2015
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million peopleThe Lancet Diabetes & Endocrinology, 2014
- The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque CountryBMC Public Health, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Changes in Diabetes-Related Complications in the United States, 1990–2010The New England Journal of Medicine, 2014
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureThe New England Journal of Medicine, 1987